Compare GROY & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROY | CMPX |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 938.2M | 926.7M |
| IPO Year | 2021 | N/A |
| Metric | GROY | CMPX |
|---|---|---|
| Price | $4.94 | $5.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $5.15 | ★ $13.44 |
| AVG Volume (30 Days) | ★ 3.0M | 2.5M |
| Earning Date | 11-05-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,464,000.00 | N/A |
| Revenue This Year | $72.11 | N/A |
| Revenue Next Year | $100.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 86.30 | N/A |
| 52 Week Low | $1.20 | $1.33 |
| 52 Week High | $5.05 | $6.25 |
| Indicator | GROY | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 75.93 | 58.06 |
| Support Level | $4.16 | $5.09 |
| Resistance Level | $4.45 | $6.25 |
| Average True Range (ATR) | 0.19 | 0.43 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 90.54 | 64.04 |
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.